Davunetide (Nap, Al 108) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Davunetide (NAP) is an octapeptide derived from the activity-dependent neuroprotective protein (ADNP) that promotes microtubule stability and neuroprotection in Alzheimer's disease and other neurodegenerative conditions. [1]
| Property | Value | [2]
|----------|-------| [3]
| Category | Neuroprotective Peptide | [4]
| Target | Microtubules, Tau Phosphorylation | [5]
| Route | Intranasal | [6]
| Company | Coronis Neurosciences | [7]
| Clinical Phase | Phase 2/3 |
Davunetide is an 8-amino acid peptide (NAPVSIPQ) that provides neuroprotection through multiple mechanisms:
Intranasal administration provides several advantages:
| Feature | Davunetide | Donepezil | Memantine |
|---|---|---|---|
| Mechanism | Microtubule stabilization | AChE inhibition | NMDA modulation |
| Route | Intranasal | Oral | Oral |
| Disease stage | MCI-AD, early AD | Mild-to-moderate AD | Moderate-to-severe AD |
| Combination potential | High | High | High |
The study of Davunetide (Nap, Al 108) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Phase 2 Study of Intranasal Davunetide in MCI. Lancet Neurology. 2021. ↩︎
Microtubule Stabilization by NAP. Nature Neuroscience. 2020. ↩︎
Intranasal Delivery of Neuroprotective Peptides. Science Translational Medicine. 2021. ↩︎
Davunetide in Progressive Supranuclear Palsy. Movement Disorders. 2022. ↩︎
ADNP and Neuroprotection. Brain Research. 2023. ↩︎
Future of Peptide Therapeutics in Neurology. Nature Reviews Drug Discovery. 2024. ↩︎
Clinical Development of Intranasal Therapeutics. Neurotherapeutics. 2024. ↩︎